Topics

Neuraly Company Profile

14:15 EDT 6th April 2020 | BioPortfolio

NLY01 is a proprietary long-acting analogue of exendin-4, a glucagon-like peptide-1 receptor (GLP-1R) agonist. NLY01 penetrates the blood-brain barrier (BBB) in animal models and its receptor (GLP-1R) is highly expressed on glial cells. NLY01 is being developed as a disease-modifying agent for neurodegenerative disorders including Parkinson’s and Alzheimer’s disease. In clinically relevant animal models, NLY01 was found to prevent neuronal cell death by inhibition of microglial activation and formation of A1 neurotoxic astroglial cells. Treatment with NLY01 slowed disease progression, improved motor and cognitive functions and extended the lifespan in mice with Parkinson’s disease.


News Articles [2 Associated News Articles listed on BioPortfolio]

CORRECTING and REPLACING Neuraly Announces First Patient Dosed in Phase 2 Clinical Trial of NLY01 for Patients with Parkinson’s Disease

Novel Mechanism of Action Inhibits Pathological Activation of Microglial Cells and Prevents Neuronal Cell Death All mentions of NLY01 have been corrected. The corrected release reads: NEURALY AN...

Neuraly Announces First Patient Dosed in Phase 2 Clinical Trial of NYL01 for Patients with Parkinson’s Disease

Novel Mechanism of Action Inhibits Pathological Activation of Microglial Cells and Prevents Neuronal Cell Death Neuraly, a clinical stage biotechnology company pioneering disease-modifying agents fo...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [2 Associated Companies listed on BioPortfolio]

D&D Pharmatech Inc.

D&D Pharmatech is a clinical-stage global biotech company that funds the development of revolutionary medicines through disease-specific subsidiary companies founded and guided by top-tier medical re...

Neuraly

NLY01 is a proprietary long-acting analogue of exendin-4, a glucagon-like peptide-1 receptor (GLP-1R) agonist. NLY01 penetrates the blood-brain barrier (BBB) in animal models and its receptor (GLP-1R...

More Information about "Neuraly" on BioPortfolio

We have published hundreds of Neuraly news stories on BioPortfolio along with dozens of Neuraly Clinical Trials and PubMed Articles about Neuraly for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Neuraly Companies in our database. You can also find out about relevant Neuraly Drugs and Medications on this site too.

Quick Search

Corporate Database Quicklinks



Searches Linking to this Company Record